Literature DB >> 19073250

Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia.

Stéphanie Pannier1, Vincent Couloigner, Nadia Messaddeq, Monique Elmaleh-Bergès, Arnold Munnich, Raymond Romand, Laurence Legeai-Mallet.   

Abstract

Fibroblast growth factor receptor 3 (FGFR3) is a key regulator of skeletal development and activating mutations in FGFR3 cause skeletal dysplasias, including hypochondroplasia, achondroplasia and thanatophoric dysplasia. The introduction of the Y367C mutation corresponding to the human Y373C thanatophoric dysplasia type I (TDI) mutation into the mouse genome, resulted in dwarfism with a skeletal phenotype remarkably similar to that of human chondrodysplasia. To investigate the role of the activating Fgfr3 Y367C mutation in auditory function, the middle and inner ear of the heterozygous mutant Fgfr3(Y367C/+) mice were examined. The mutant Fgfr3(Y367C/+) mice exhibit fully penetrant deafness with a significantly elevated auditory brainstem response threshold for all frequencies tested. The inner ear defect is mainly associated with an increased number of pillar cells or modified supporting cells in the organ of Corti. Hearing loss in the Fgfr3(Y367C/+) mouse model demonstrates the crucial role of Fgfr3 in the development of the inner ear and provides novel insight on the biological consequences of FGFR3 mutations in chondrodysplasia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073250     DOI: 10.1016/j.bbadis.2008.11.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  Extremely discrepant mutation spectrum of SLC26A4 between Chinese patients with isolated Mondini deformity and enlarged vestibular aqueduct.

Authors:  Shasha Huang; Dongyi Han; Yongyi Yuan; Guojian Wang; Dongyang Kang; Xin Zhang; Xiaofei Yan; Xiaoxiao Meng; Min Dong; Pu Dai
Journal:  J Transl Med       Date:  2011-09-30       Impact factor: 5.531

Review 2.  Hearing loss in syndromic craniosynostoses: introduction and consideration of mechanisms.

Authors:  Nneamaka B Agochukwu; Benjamin D Solomon; Maximilian Muenke
Journal:  Am J Audiol       Date:  2014-06       Impact factor: 1.493

Review 3.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

4.  CD44 is a marker for the outer pillar cells in the early postnatal mouse inner ear.

Authors:  Ronna Hertzano; Chandrakala Puligilla; Siaw-Lin Chan; Caroline Timothy; Didier A Depireux; Zubair Ahmed; Jeffrey Wolf; David J Eisenman; Thomas B Friedman; Sheikh Riazuddin; Matthew W Kelley; Scott E Strome
Journal:  J Assoc Res Otolaryngol       Date:  2010-04-13

5.  The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice.

Authors:  Ramiro E Toribio; Holly A Brown; Chad M Novince; Brandlyn Marlow; Krista Hernon; Lisa G Lanigan; Blake E Hildreth; Jillian L Werbeck; Sherry T Shu; Gwendolen Lorch; Michelle Carlton; John Foley; Prosper Boyaka; Laurie K McCauley; Thomas J Rosol
Journal:  FASEB J       Date:  2010-02-09       Impact factor: 5.191

6.  Crouzon syndrome with acanthosis nigricans: a case-based update.

Authors:  Federico Di Rocco; Corinne Collet; Laurence Legeai-Mallet; Eric Arnaud; Martine Le Merrer; Smail Hadj-Rabia; Dominique Renier
Journal:  Childs Nerv Syst       Date:  2010-12-07       Impact factor: 1.475

7.  Regulation of cell fate and patterning in the developing mammalian cochlea.

Authors:  Matthew W Kelley; Elizabeth C Driver; Chandrakala Puligilla
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2009-10       Impact factor: 2.064

8.  Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Authors:  Davide Komla-Ebri; Emilie Dambroise; Ina Kramer; Catherine Benoist-Lasselin; Nabil Kaci; Cindy Le Gall; Ludovic Martin; Patricia Busca; Florent Barbault; Diana Graus-Porta; Arnold Munnich; Michaela Kneissel; Federico Di Rocco; Martin Biosse-Duplan; Laurence Legeai-Mallet
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

9.  FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.

Authors:  Yaron Hadari; Joseph Schlessinger
Journal:  J Clin Invest       Date:  2009-05       Impact factor: 14.808

10.  A requirement for Fgfr2 in middle ear development.

Authors:  Diana Rigueur; Ryan R Roberts; Lauren Bobzin; Amy E Merrill
Journal:  Genesis       Date:  2018-10-04       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.